首页 > 最新文献

Journal of Transplantation最新文献

英文 中文
The Utility of Routine Ultrasound Imaging after Elective Transplant Ureteric Stent Removal. 择期输尿管支架置换术后常规超声成像的应用。
IF 2.5 Q3 SURGERY Pub Date : 2016-01-01 Epub Date: 2016-07-14 DOI: 10.1155/2016/1231567
Bibek Das, Dorian Hobday, Jonathon Olsburgh, Chris Callaghan

Background. Ureteric stent insertion during kidney transplantation reduces the incidence of major urological complications (MUCs). We evaluated whether routine poststent removal graft ultrasonography (PSRGU) was useful in detecting MUCs before they became clinically or biochemically apparent. Methods. A retrospective analysis was undertaken of clinical outcomes following elective stent removals from adult single renal transplant recipients (sRTRs) at our centre between 1 January 2011 and 31 December 2013. Results. Elective stent removal was performed for 338 sRTRs. Of these patients, 222 had routine PSRGU (median (IQR) days after stent removal = 18 (11-31)), 79 had urgent PSRGU due to clinical or biochemical indications, 12 had CT imaging, and 25 had no further renal imaging. Of the 222 sRTRs who underwent routine PSRGU, 210 (94.6%) had no change of management, three (1.4%) required repeat imaging only, and eight patients (3.6%) had incidental (nonureteric) findings. One patient (0.5%) had nephrostomy insertion as a result of routine PSRGU findings, but no ureteric stenosis was identified. Of 79 patients having urgent PSRGU after elective stent removal, three patients required transplant ureteric reimplantation. Conclusions. This analysis found no evidence that routine PSRGU at two to three weeks after elective stent removal provides any added value beyond standard clinical and biochemical monitoring.

背景。肾移植期间输尿管支架置入可减少主要泌尿系统并发症(MUCs)的发生率。我们评估了常规支架移除后移植超声检查(PSRGU)在MUCs临床或生化表现明显之前是否有用。方法。回顾性分析本中心2011年1月1日至2013年12月31日期间成人单肾移植受者(sRTRs)择期支架移除后的临床结果。结果。338例srtr患者行择期支架取出术。在这些患者中,222例为常规PSRGU(支架取出后的中位(IQR)天= 18(11-31)),79例因临床或生化适应症而紧急PSRGU, 12例进行了CT成像,25例没有进一步的肾脏影像学检查。在222例接受常规PSRGU的srtr患者中,210例(94.6%)没有改变治疗方法,3例(1.4%)只需要重复成像,8例(3.6%)有偶发(非输尿管)发现。1例患者(0.5%)因常规PSRGU检查结果行肾造口术,但未发现输尿管狭窄。79例择期支架取出后出现紧急PSRGU的患者中,3例患者需要输尿管移植再植。结论。该分析发现,在选择性支架移除后2 - 3周的常规PSRGU除了标准的临床和生化监测外,没有任何证据表明其有任何附加价值。
{"title":"The Utility of Routine Ultrasound Imaging after Elective Transplant Ureteric Stent Removal.","authors":"Bibek Das,&nbsp;Dorian Hobday,&nbsp;Jonathon Olsburgh,&nbsp;Chris Callaghan","doi":"10.1155/2016/1231567","DOIUrl":"https://doi.org/10.1155/2016/1231567","url":null,"abstract":"<p><p>Background. Ureteric stent insertion during kidney transplantation reduces the incidence of major urological complications (MUCs). We evaluated whether routine poststent removal graft ultrasonography (PSRGU) was useful in detecting MUCs before they became clinically or biochemically apparent. Methods. A retrospective analysis was undertaken of clinical outcomes following elective stent removals from adult single renal transplant recipients (sRTRs) at our centre between 1 January 2011 and 31 December 2013. Results. Elective stent removal was performed for 338 sRTRs. Of these patients, 222 had routine PSRGU (median (IQR) days after stent removal = 18 (11-31)), 79 had urgent PSRGU due to clinical or biochemical indications, 12 had CT imaging, and 25 had no further renal imaging. Of the 222 sRTRs who underwent routine PSRGU, 210 (94.6%) had no change of management, three (1.4%) required repeat imaging only, and eight patients (3.6%) had incidental (nonureteric) findings. One patient (0.5%) had nephrostomy insertion as a result of routine PSRGU findings, but no ureteric stenosis was identified. Of 79 patients having urgent PSRGU after elective stent removal, three patients required transplant ureteric reimplantation. Conclusions. This analysis found no evidence that routine PSRGU at two to three weeks after elective stent removal provides any added value beyond standard clinical and biochemical monitoring. </p>","PeriodicalId":45795,"journal":{"name":"Journal of Transplantation","volume":"2016 ","pages":"1231567"},"PeriodicalIF":2.5,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/1231567","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34733846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Current Treatment Approaches to HCC with a Special Consideration to Transplantation. 当前肝细胞癌的治疗方法,特别考虑移植。
IF 2.5 Q3 SURGERY Pub Date : 2016-01-01 Epub Date: 2016-06-20 DOI: 10.1155/2016/7926264
N Bhardwaj, M T P R Perera, M A Silva

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. The mainstay of treatment of HCC has been both resectional and transplantation surgery. It is well known that, in selected, optimized patients, hepatectomy for HCC may be an option, even in patients with underlying cirrhosis. Resectable patients with early HCC and underlying liver disease are however increasingly being considered for transplantation because of potential for better disease-free survival and resolution of underlying liver disease, although this approach is limited by the availability of donor livers, especially in resectable patients. Outcomes following liver transplantation improved dramatically for patients with HCC following the implementation of the Milan criteria in the late 1990s. Ever since, the rather restrictive nature of the Milan criteria has been challenged with good outcomes. There has also been an increase in the donor pool with marginal donors including organs retrieved following cardiac death being used. Even so, patients still continue to die while waiting for a liver transplant. In order to reduce this attrition, bridging techniques and methods for downstaging disease have evolved. Additionally new techniques for organ preservation have increased the prospect of this potentially curative procedure being available for a greater number of patients.

肝细胞癌(HCC)是全球癌症死亡的第三大原因。肝细胞癌的主要治疗方法是切除和移植手术。众所周知,在选定的、优化的患者中,肝切除术治疗HCC可能是一种选择,即使是有潜在肝硬化的患者。然而,可切除的早期HCC和潜在肝病患者越来越多地被考虑进行移植,因为有可能获得更好的无病生存和潜在肝病的解决,尽管这种方法受到供体肝脏的可用性的限制,特别是在可切除的患者中。在20世纪90年代末实施米兰标准后,肝移植后HCC患者的预后显著改善。从那以后,米兰标准的限制性受到了良好结果的挑战。供体池也有所增加,边缘供体包括使用心脏死亡后取出的器官。即便如此,仍有患者在等待肝移植的过程中死亡。为了减少这种消耗,桥接技术和降低分期疾病的方法已经发展。此外,器官保存的新技术增加了这种潜在治疗程序的前景,可用于更多的患者。
{"title":"Current Treatment Approaches to HCC with a Special Consideration to Transplantation.","authors":"N Bhardwaj,&nbsp;M T P R Perera,&nbsp;M A Silva","doi":"10.1155/2016/7926264","DOIUrl":"https://doi.org/10.1155/2016/7926264","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. The mainstay of treatment of HCC has been both resectional and transplantation surgery. It is well known that, in selected, optimized patients, hepatectomy for HCC may be an option, even in patients with underlying cirrhosis. Resectable patients with early HCC and underlying liver disease are however increasingly being considered for transplantation because of potential for better disease-free survival and resolution of underlying liver disease, although this approach is limited by the availability of donor livers, especially in resectable patients. Outcomes following liver transplantation improved dramatically for patients with HCC following the implementation of the Milan criteria in the late 1990s. Ever since, the rather restrictive nature of the Milan criteria has been challenged with good outcomes. There has also been an increase in the donor pool with marginal donors including organs retrieved following cardiac death being used. Even so, patients still continue to die while waiting for a liver transplant. In order to reduce this attrition, bridging techniques and methods for downstaging disease have evolved. Additionally new techniques for organ preservation have increased the prospect of this potentially curative procedure being available for a greater number of patients. </p>","PeriodicalId":45795,"journal":{"name":"Journal of Transplantation","volume":"2016 ","pages":"7926264"},"PeriodicalIF":2.5,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/7926264","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34731314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 17
For and against Organ Donation and Transplantation: Intricate Facilitators and Barriers in Organ Donation Perceived by German Nurses and Doctors. 支持和反对器官捐献与移植:德国护士和医生眼中器官捐献中错综复杂的促进因素和障碍。
IF 2.5 Q3 SURGERY Pub Date : 2016-01-01 Epub Date: 2016-08-15 DOI: 10.1155/2016/3454601
Niels Christian Hvidt, Beate Mayr, Piret Paal, Eckhard Frick, Anna Forsberg, Arndt Büssing

Background. Significant facilitators and barriers to organ donation and transplantation remain in the general public and even in health professionals. Negative attitudes of HPs have been identified as the most significant barrier to actual ODT. The purpose of this paper was hence to investigate to what extent HPs (physicians and nurses) experience such facilitators and barriers in ODT and to what extent they are intercorrelated. We thus combined single causes to circumscribed factors of respective barriers and facilitators and analyzed them for differences regarding profession, gender, spiritual/religious self-categorization, and self-estimated knowledge of ODT and their mutual interaction. Methods. By the use of questionnaires we investigated intricate facilitators and barriers to organ donation experienced by HPs (n = 175; 73% nurses, 27% physicians) in around ten wards at the University Hospital of Munich. Results. Our study confirms a general high agreement with the importance of ODT. Nevertheless, we identified both facilitators and barriers in the following fields: (1) knowledge of ODT and willingness to donate own organs, (2) ethical delicacies in ODT, (3) stressors to handle ODT in the hospital, and (4) individual beliefs and self-estimated religion/spirituality. Conclusion. Attention to the intricacy of stressors and barriers in HPs continues to be a high priority focus for the availability of donor organs.

背景。一般公众,甚至卫生专业人员对器官捐献和移植仍然存在重大的促进因素和障碍。医护人员的消极态度被认为是实际进行器官捐献和移植的最大障碍。因此,本文的目的是调查医护人员(医生和护士)在器官捐献和移植过程中遇到的促进因素和障碍的程度,以及它们之间的相互关联程度。因此,我们将各自障碍和促进因素的单一原因与限定因素相结合,并分析了它们在职业、性别、精神/宗教自我归类和自我估计的 ODT 知识方面的差异及其相互影响。研究方法通过问卷调查,我们调查了慕尼黑大学医院十个病房的医护人员(n = 175;73%为护士,27%为医生)在器官捐献方面遇到的错综复杂的促进因素和障碍。研究结果我们的研究证实,人们普遍高度认同器官捐献的重要性。不过,我们在以下几个方面发现了促进因素和障碍:(1) 对无偿献血的了解和捐献自身器官的意愿,(2) 无偿献血中的道德问题,(3) 医院处理无偿献血的压力,(4) 个人信仰和自我估计的宗教/精神。结论。关注 HPs 中错综复杂的压力和障碍仍是提供器官捐献的重中之重。
{"title":"For and against Organ Donation and Transplantation: Intricate Facilitators and Barriers in Organ Donation Perceived by German Nurses and Doctors.","authors":"Niels Christian Hvidt, Beate Mayr, Piret Paal, Eckhard Frick, Anna Forsberg, Arndt Büssing","doi":"10.1155/2016/3454601","DOIUrl":"10.1155/2016/3454601","url":null,"abstract":"<p><p>Background. Significant facilitators and barriers to organ donation and transplantation remain in the general public and even in health professionals. Negative attitudes of HPs have been identified as the most significant barrier to actual ODT. The purpose of this paper was hence to investigate to what extent HPs (physicians and nurses) experience such facilitators and barriers in ODT and to what extent they are intercorrelated. We thus combined single causes to circumscribed factors of respective barriers and facilitators and analyzed them for differences regarding profession, gender, spiritual/religious self-categorization, and self-estimated knowledge of ODT and their mutual interaction. Methods. By the use of questionnaires we investigated intricate facilitators and barriers to organ donation experienced by HPs (n = 175; 73% nurses, 27% physicians) in around ten wards at the University Hospital of Munich. Results. Our study confirms a general high agreement with the importance of ODT. Nevertheless, we identified both facilitators and barriers in the following fields: (1) knowledge of ODT and willingness to donate own organs, (2) ethical delicacies in ODT, (3) stressors to handle ODT in the hospital, and (4) individual beliefs and self-estimated religion/spirituality. Conclusion. Attention to the intricacy of stressors and barriers in HPs continues to be a high priority focus for the availability of donor organs. </p>","PeriodicalId":45795,"journal":{"name":"Journal of Transplantation","volume":"2016 ","pages":"3454601"},"PeriodicalIF":2.5,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34710456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence, Characteristics, and Prognosis of Incidentally Discovered Hepatocellular Carcinoma after Liver Transplantation. 肝移植术后偶然发现的肝细胞癌的发生率、特点及预后。
IF 2.5 Q3 SURGERY Pub Date : 2016-01-01 Epub Date: 2016-06-15 DOI: 10.1155/2016/1916387
Walid El Moghazy, Samy Kashkoush, Glenda Meeberg, Norman Kneteman

Background. We aimed to assess incidentally discovered hepatocellular carcinoma (iHCC) over time and to compare outcome to preoperatively diagnosed hepatocellular carcinoma (pdHCC) and nontumor liver transplants. Methods. We studied adults transplanted with a follow-up of at least one year. Patients were divided into 3 groups according to diagnosis of hepatocellular carcinoma. Results. Between 1990 and 2010, 887 adults were transplanted. Among them, 121 patients (13.6%) had pdHCC and 32 patients (3.6%) had iHCC; frequency of iHCC decreased markedly over years, in parallel with significant increase in pdHCC. Between 1990 and 1995, 120 patients had liver transplants, 4 (3.3%) of them had iHCC, and only 3 (2.5%) had pdHCC, while in the last 5 years, 263 patients were transplanted, 7 (0.03%) of them had iHCC, and 66 (25.1%) had pdHCC (P < 0.001). There was no significant difference between groups regarding patient survival; 5-year survival was 74%, 75.5%, and 77.3% in iHCC, pdHCC, and non-HCC groups, respectively (P = 0.702). Patients with iHCC had no recurrences after transplant, while pdHCC patients experienced 17 recurrences (15.3%) (P = 0.016). Conclusions. iHCC has significantly decreased despite steady increase in number of transplants for hepatocellular carcinoma. Patients with iHCC had excellent outcomes with no tumor recurrence and survival comparable to pdHCC.

背景。我们的目的是评估偶然发现的肝细胞癌(iHCC)随着时间的推移,并比较术前诊断的肝细胞癌(pdHCC)和非肿瘤肝移植的结果。方法。我们对成人移植进行了至少一年的随访研究。根据肝细胞癌的诊断情况将患者分为3组。结果。在1990年至2010年间,移植了887株成虫。其中pdHCC 121例(13.6%),iHCC 32例(3.6%);iHCC的发病率逐年显著下降,与此同时pdHCC的发病率显著增加。1990 - 1995年间,肝移植患者120例,iHCC患者4例(3.3%),pdHCC患者3例(2.5%),而近5年,肝移植患者263例,iHCC患者7例(0.03%),pdHCC患者66例(25.1%)(P < 0.001)。两组患者生存率无显著差异;iHCC、pdHCC和非hcc组的5年生存率分别为74%、75.5%和77.3% (P = 0.702)。移植后iHCC患者无复发,pdHCC患者有17例(15.3%)复发(P = 0.016)。结论。尽管肝细胞癌移植数量稳步增加,但iHCC已显著减少。iHCC患者预后良好,无肿瘤复发,生存期与pdHCC相当。
{"title":"Incidence, Characteristics, and Prognosis of Incidentally Discovered Hepatocellular Carcinoma after Liver Transplantation.","authors":"Walid El Moghazy,&nbsp;Samy Kashkoush,&nbsp;Glenda Meeberg,&nbsp;Norman Kneteman","doi":"10.1155/2016/1916387","DOIUrl":"https://doi.org/10.1155/2016/1916387","url":null,"abstract":"<p><p>Background. We aimed to assess incidentally discovered hepatocellular carcinoma (iHCC) over time and to compare outcome to preoperatively diagnosed hepatocellular carcinoma (pdHCC) and nontumor liver transplants. Methods. We studied adults transplanted with a follow-up of at least one year. Patients were divided into 3 groups according to diagnosis of hepatocellular carcinoma. Results. Between 1990 and 2010, 887 adults were transplanted. Among them, 121 patients (13.6%) had pdHCC and 32 patients (3.6%) had iHCC; frequency of iHCC decreased markedly over years, in parallel with significant increase in pdHCC. Between 1990 and 1995, 120 patients had liver transplants, 4 (3.3%) of them had iHCC, and only 3 (2.5%) had pdHCC, while in the last 5 years, 263 patients were transplanted, 7 (0.03%) of them had iHCC, and 66 (25.1%) had pdHCC (P < 0.001). There was no significant difference between groups regarding patient survival; 5-year survival was 74%, 75.5%, and 77.3% in iHCC, pdHCC, and non-HCC groups, respectively (P = 0.702). Patients with iHCC had no recurrences after transplant, while pdHCC patients experienced 17 recurrences (15.3%) (P = 0.016). Conclusions. iHCC has significantly decreased despite steady increase in number of transplants for hepatocellular carcinoma. Patients with iHCC had excellent outcomes with no tumor recurrence and survival comparable to pdHCC. </p>","PeriodicalId":45795,"journal":{"name":"Journal of Transplantation","volume":"2016 ","pages":"1916387"},"PeriodicalIF":2.5,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/1916387","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34659629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Effectively Screening for Coronary Artery Disease in Patients Undergoing Orthotopic Liver Transplant Evaluation. 原位肝移植患者冠状动脉病变的有效筛查
IF 2.5 Q3 SURGERY Pub Date : 2016-01-01 Epub Date: 2016-06-22 DOI: 10.1155/2016/7187206
Bryan C Lee, Feng Li, Adam J Hanje, Khalid Mumtaz, Konstantinos D Boudoulas, Scott M Lilly

Coronary artery disease (CAD) is prevalent in patients with end-stage liver disease and associated with poor outcomes when undergoing orthotopic liver transplantation (OLT); however, noninvasive screening for CAD in this population is less sensitive. In an attempt to identify redundancy, we reviewed our experience among patients undergoing CAD screening as part of their OLT evaluation between May 2009 and February 2014. Demographic, clinical, and procedural characteristics were analyzed. Of the total number of screened patients (n = 132), initial screening was more common via stress testing (n = 100; 75.8%) than coronary angiography (n = 32; 24.2%). Most with initial stress testing underwent angiography (n = 52; 39.4%). Among those undergoing angiography, CAD was common (n = 31; 23.5%). Across the entire cohort the number of traditional risk factors was linearly associated with CAD, and those with two or more risk factors were found to have CAD by angiography 50% of the time (OR 1.92; CI 1.07-3.44, p = 0.026). Our data supports that CAD is prevalent among pre-OLT patients, especially among those with 2 or more risk factors. Moreover, we identified a lack of uniformity in practice and the need for evidence-based and standardized screening protocols.

冠状动脉疾病(CAD)在终末期肝病患者中普遍存在,并与原位肝移植(OLT)的不良预后相关;然而,在这一人群中,非侵入性CAD筛查的敏感性较低。为了识别冗余,我们回顾了2009年5月至2014年2月期间接受CAD筛查作为OLT评估一部分的患者的经验。分析了人口统计学、临床和手术特点。在接受筛查的患者总数(n = 132)中,最初的筛查更常见的是通过压力测试(n = 100;75.8%)高于冠状动脉造影(n = 32;24.2%)。大多数初始压力测试患者接受血管造影(n = 52;39.4%)。在接受血管造影的患者中,CAD很常见(n = 31;23.5%)。在整个队列中,传统危险因素的数量与CAD呈线性相关,血管造影发现有两个或两个以上危险因素的患者有50%的时间患有CAD (or 1.92;CI 1.07-3.44, p = 0.026)。我们的数据支持CAD在olt前患者中普遍存在,特别是在有2个或更多危险因素的患者中。此外,我们发现在实践中缺乏统一性,需要循证和标准化的筛查方案。
{"title":"Effectively Screening for Coronary Artery Disease in Patients Undergoing Orthotopic Liver Transplant Evaluation.","authors":"Bryan C Lee,&nbsp;Feng Li,&nbsp;Adam J Hanje,&nbsp;Khalid Mumtaz,&nbsp;Konstantinos D Boudoulas,&nbsp;Scott M Lilly","doi":"10.1155/2016/7187206","DOIUrl":"https://doi.org/10.1155/2016/7187206","url":null,"abstract":"<p><p>Coronary artery disease (CAD) is prevalent in patients with end-stage liver disease and associated with poor outcomes when undergoing orthotopic liver transplantation (OLT); however, noninvasive screening for CAD in this population is less sensitive. In an attempt to identify redundancy, we reviewed our experience among patients undergoing CAD screening as part of their OLT evaluation between May 2009 and February 2014. Demographic, clinical, and procedural characteristics were analyzed. Of the total number of screened patients (n = 132), initial screening was more common via stress testing (n = 100; 75.8%) than coronary angiography (n = 32; 24.2%). Most with initial stress testing underwent angiography (n = 52; 39.4%). Among those undergoing angiography, CAD was common (n = 31; 23.5%). Across the entire cohort the number of traditional risk factors was linearly associated with CAD, and those with two or more risk factors were found to have CAD by angiography 50% of the time (OR 1.92; CI 1.07-3.44, p = 0.026). Our data supports that CAD is prevalent among pre-OLT patients, especially among those with 2 or more risk factors. Moreover, we identified a lack of uniformity in practice and the need for evidence-based and standardized screening protocols. </p>","PeriodicalId":45795,"journal":{"name":"Journal of Transplantation","volume":"2016 ","pages":"7187206"},"PeriodicalIF":2.5,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/7187206","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34672714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Intermediate-Term Outcomes of Dual Adult versus Single-Kidney Transplantation: Evolution of a Surgical Technique. 成人双肾移植与单肾移植的中期结果:一种手术技术的演变。
IF 2.5 Q3 SURGERY Pub Date : 2016-01-01 Epub Date: 2016-07-10 DOI: 10.1155/2016/2586761
Ana K Islam, Richard J Knight, Wesley A Mayer, Adam B Hollander, Samir Patel, Larry D Teeter, Edward A Graviss, Ashish Saharia, Hemangshu Podder, Emad H Asham, A Osama Gaber

Background. Acceptance of dual kidney transplantation (DKT) has proven difficult, due to surgical complexity and concerns regarding long-term outcomes. We herein present a standard technique for ipsilateral DKT and compare outcomes to single-kidney transplant (SKT) recipients. Methods. A retrospective single-center comparison of DKT and SKT performed between February 2007 and July 2013. Results. Of 516 deceased donor kidney transplants, 29 were DKT and 487 were SKT. Mean follow-up was 43 ± 67 months. DKT recipients were older and more likely than SKT recipients to receive an extended criteria graft (p < 0.001). For DKT versus SKT, the rates of delayed graft function (10.3 versus 9.2%) and acute rejection (20.7 versus 22.4%) were equivalent (p = ns). A higher than expected urologic complication rate in the DKT cohort (14 versus 2%, p < 0.01) was reduced through modification of the ureteral anastomosis. Graft survival was equivalent between DKT and SKT groups (p = ns) with actuarial 3-year DKT patient and graft survivals of 100% and 93%. At 3 years, the groups had similar renal function (p = ns). Conclusions. By utilizing extended criteria donor organs as DKT, the donor pool was enlarged while providing excellent patient and graft survival. The DKT urologic complication rate was reduced by modification of the ureteral anastomosis.

背景。由于手术复杂性和对长期预后的担忧,双肾移植(DKT)的接受被证明是困难的。我们在此提出了同侧DKT的标准技术,并比较了单肾移植(SKT)接受者的结果。方法。2007年2月至2013年7月对DKT和SKT进行回顾性单中心比较。结果。在516例死亡供体肾脏移植中,29例为DKT, 487例为SKT。平均随访43±67个月。DKT受者年龄较大,比SKT受者更有可能接受扩展标准移植(p < 0.001)。对于DKT和SKT,延迟移植功能的比率(10.3%对9.2%)和急性排斥反应(20.7%对22.4%)是相等的(p = ns)。通过改良输尿管吻合术,降低了DKT队列中高于预期的泌尿系统并发症发生率(14%对2%,p < 0.01)。DKT组和SKT组的移植物存活率相等(p = ns),精算3年DKT患者和移植物存活率分别为100%和93%。3年时,两组肾功能相近(p = ns)。结论。通过使用扩展标准供体器官作为DKT,扩大了供体池,同时提供了良好的患者和移植物生存。改良输尿管吻合术可降低DKT泌尿系统并发症发生率。
{"title":"Intermediate-Term Outcomes of Dual Adult versus Single-Kidney Transplantation: Evolution of a Surgical Technique.","authors":"Ana K Islam,&nbsp;Richard J Knight,&nbsp;Wesley A Mayer,&nbsp;Adam B Hollander,&nbsp;Samir Patel,&nbsp;Larry D Teeter,&nbsp;Edward A Graviss,&nbsp;Ashish Saharia,&nbsp;Hemangshu Podder,&nbsp;Emad H Asham,&nbsp;A Osama Gaber","doi":"10.1155/2016/2586761","DOIUrl":"https://doi.org/10.1155/2016/2586761","url":null,"abstract":"<p><p>Background. Acceptance of dual kidney transplantation (DKT) has proven difficult, due to surgical complexity and concerns regarding long-term outcomes. We herein present a standard technique for ipsilateral DKT and compare outcomes to single-kidney transplant (SKT) recipients. Methods. A retrospective single-center comparison of DKT and SKT performed between February 2007 and July 2013. Results. Of 516 deceased donor kidney transplants, 29 were DKT and 487 were SKT. Mean follow-up was 43 ± 67 months. DKT recipients were older and more likely than SKT recipients to receive an extended criteria graft (p < 0.001). For DKT versus SKT, the rates of delayed graft function (10.3 versus 9.2%) and acute rejection (20.7 versus 22.4%) were equivalent (p = ns). A higher than expected urologic complication rate in the DKT cohort (14 versus 2%, p < 0.01) was reduced through modification of the ureteral anastomosis. Graft survival was equivalent between DKT and SKT groups (p = ns) with actuarial 3-year DKT patient and graft survivals of 100% and 93%. At 3 years, the groups had similar renal function (p = ns). Conclusions. By utilizing extended criteria donor organs as DKT, the donor pool was enlarged while providing excellent patient and graft survival. The DKT urologic complication rate was reduced by modification of the ureteral anastomosis. </p>","PeriodicalId":45795,"journal":{"name":"Journal of Transplantation","volume":"2016 ","pages":"2586761"},"PeriodicalIF":2.5,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/2586761","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34720599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update. 依维莫司与实体器官移植后的恶性肿瘤:临床进展。
IF 2.5 Q3 SURGERY Pub Date : 2016-01-01 Epub Date: 2016-10-11 DOI: 10.1155/2016/4369574
Hallvard Holdaas, Paolo De Simone, Andreas Zuckermann
Malignancy after solid organ transplantation remains a major cause of posttransplant mortality. The mammalian target of rapamycin (mTOR) inhibitor class of immunosuppressants exerts various antioncogenic effects, and the mTOR inhibitor everolimus is licensed for the treatment of several solid cancers. In kidney transplantation, evidence from registry studies indicates a lower rate of de novo malignancy under mTOR inhibition, with some potentially supportive data from randomized trials of everolimus. Case reports and small single-center series have suggested that switch to everolimus may be beneficial following diagnosis of posttransplant malignancy, particularly for Kaposi's sarcoma and nonmelanoma skin cancer, but prospective studies are lacking. A systematic review has shown mTOR inhibition to be associated with a significantly lower rate of hepatocellular carcinoma (HCC) recurrence versus standard calcineurin inhibitor therapy. One meta-analysis has concluded that patients with nontransplant HCC experience a low but significant survival benefit under everolimus monotherapy, so far unconfirmed in a transplant population. Data are limited in heart transplantation, although observational data and case reports have indicated that introduction of everolimus is helpful in reducing the recurrence of skin cancers. Overall, it can be concluded that, in certain settings, everolimus appears a promising option to lessen the toll of posttransplant malignancy.
实体器官移植后的恶性肿瘤仍然是移植后死亡的主要原因。哺乳动物靶向雷帕霉素(mTOR)抑制剂类免疫抑制剂具有多种抗原性作用,mTOR抑制剂依维莫司被许可用于治疗几种实体癌症。在肾移植中,来自注册研究的证据表明,mTOR抑制下的新发恶性肿瘤发生率较低,依维莫司随机试验的一些潜在支持数据。病例报告和小型单中心研究表明,移植后恶性肿瘤诊断后改用依维莫司可能是有益的,特别是卡波西肉瘤和非黑色素瘤皮肤癌,但缺乏前瞻性研究。一项系统综述显示,与标准钙调磷酸酶抑制剂治疗相比,mTOR抑制与肝细胞癌(HCC)复发率显著降低相关。一项荟萃分析得出结论,非移植性HCC患者在依维莫司单药治疗下生存率低但显著,迄今尚未在移植人群中得到证实。尽管观察数据和病例报告表明,依维莫司的引入有助于减少皮肤癌的复发,但在心脏移植方面的数据有限。总的来说,可以得出结论,在某些情况下,依维莫司似乎是一个有希望的选择,以减少移植后恶性肿瘤的死亡。
{"title":"Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update.","authors":"Hallvard Holdaas, Paolo De Simone, Andreas Zuckermann","doi":"10.1155/2016/4369574","DOIUrl":"10.1155/2016/4369574","url":null,"abstract":"Malignancy after solid organ transplantation remains a major cause of posttransplant mortality. The mammalian target of rapamycin (mTOR) inhibitor class of immunosuppressants exerts various antioncogenic effects, and the mTOR inhibitor everolimus is licensed for the treatment of several solid cancers. In kidney transplantation, evidence from registry studies indicates a lower rate of de novo malignancy under mTOR inhibition, with some potentially supportive data from randomized trials of everolimus. Case reports and small single-center series have suggested that switch to everolimus may be beneficial following diagnosis of posttransplant malignancy, particularly for Kaposi's sarcoma and nonmelanoma skin cancer, but prospective studies are lacking. A systematic review has shown mTOR inhibition to be associated with a significantly lower rate of hepatocellular carcinoma (HCC) recurrence versus standard calcineurin inhibitor therapy. One meta-analysis has concluded that patients with nontransplant HCC experience a low but significant survival benefit under everolimus monotherapy, so far unconfirmed in a transplant population. Data are limited in heart transplantation, although observational data and case reports have indicated that introduction of everolimus is helpful in reducing the recurrence of skin cancers. Overall, it can be concluded that, in certain settings, everolimus appears a promising option to lessen the toll of posttransplant malignancy.","PeriodicalId":45795,"journal":{"name":"Journal of Transplantation","volume":"2016 1","pages":"4369574"},"PeriodicalIF":2.5,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/4369574","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64382587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 54
Lung Transplantation in Patients with High Lung Allocation Scores in the US: Evidence for the Need to Evaluate Score Specific Outcomes 美国高肺分配评分患者的肺移植:需要评估评分特定结果的证据
IF 2.5 Q3 SURGERY Pub Date : 2015-12-21 DOI: 10.1155/2015/836751
J. Hayanga, Alena Lira, T. Vlahu, Jingyan Yang, J. Aboagye, Heather K. Hayanga, J. Luketich, J. D’Cunha
Objective. The lung allocation score (LAS) resulted in a lung transplantation (LT) selection process guided by clinical acuity. We sought to evaluate the relationship between LAS and outcomes. Methods. We analyzed Scientific Registry of Transplant Recipient (SRTR) data pertaining to recipients between 2005 and 2012. We stratified them into quartiles based on LAS and compared survival and predictors of mortality. Results. We identified 10,304 consecutive patients, comprising 2,576 in each LAS quartile (quartile 1 (26.3–35.5), quartile 2 (35.6–39.3), quartile 3 (39.4–48.6), and quartile 4 (48.7–95.7)). Survival after 30 days (96.9% versus 96.8% versus 96.0% versus 94.8%), 90 days (94.6% versus 93.7% versus 93.3% versus 90.9%), 1 year (87.2% versus 85.0% versus 84.8% versus 80.9%), and 5 years (55.4% versus 54.5% versus 52.5% versus 48.8%) was higher in the lower groups. There was a significantly higher 5-year mortality in the highest LAS group (HR 1.13, p = 0.030, HR 1.17, p = 0.01, and HR 1.17, p = 0.02) comparing quartiles 2, 3, and 4, respectively, to quartile 1. Conclusion. Overall, outcomes in recipients with higher LAS are worse than those in patients with lower LAS. These data should inform more individualized evidence-based discussion during pretransplant counseling.
目标。肺分配评分(LAS)导致肺移植(LT)的选择过程由临床敏锐度指导。我们试图评估LAS与预后之间的关系。方法。我们分析了2005年至2012年间移植受者的科学登记(SRTR)数据。我们根据LAS将他们分成四分位数,并比较了生存率和死亡率预测因子。结果。我们确定了10,304例连续患者,其中每个LAS四分位数(四分位数1(26.3-35.5),四分位数2(35.6-39.3),四分位数3(39.4-48.6)和四分位数4(48.7-95.7))中有2,576例。低剂量组30天生存率(96.9%对96.8%对96.0%对94.8%)、90天生存率(94.6%对93.7%对93.3%对90.9%)、1年生存率(87.2%对85.0%对84.8%对80.9%)和5年生存率(55.4%对54.5%对52.5%对48.8%)较高。与四分位数2、3和4相比,最高LAS组的5年死亡率显著高于四分位数1 (HR 1.13, p = 0.030, HR 1.17, p = 0.01, HR 1.17, p = 0.02)。结论。总体而言,高LAS患者的预后比低LAS患者差。这些数据应该为移植前咨询提供更个性化的基于证据的讨论。
{"title":"Lung Transplantation in Patients with High Lung Allocation Scores in the US: Evidence for the Need to Evaluate Score Specific Outcomes","authors":"J. Hayanga, Alena Lira, T. Vlahu, Jingyan Yang, J. Aboagye, Heather K. Hayanga, J. Luketich, J. D’Cunha","doi":"10.1155/2015/836751","DOIUrl":"https://doi.org/10.1155/2015/836751","url":null,"abstract":"Objective. The lung allocation score (LAS) resulted in a lung transplantation (LT) selection process guided by clinical acuity. We sought to evaluate the relationship between LAS and outcomes. Methods. We analyzed Scientific Registry of Transplant Recipient (SRTR) data pertaining to recipients between 2005 and 2012. We stratified them into quartiles based on LAS and compared survival and predictors of mortality. Results. We identified 10,304 consecutive patients, comprising 2,576 in each LAS quartile (quartile 1 (26.3–35.5), quartile 2 (35.6–39.3), quartile 3 (39.4–48.6), and quartile 4 (48.7–95.7)). Survival after 30 days (96.9% versus 96.8% versus 96.0% versus 94.8%), 90 days (94.6% versus 93.7% versus 93.3% versus 90.9%), 1 year (87.2% versus 85.0% versus 84.8% versus 80.9%), and 5 years (55.4% versus 54.5% versus 52.5% versus 48.8%) was higher in the lower groups. There was a significantly higher 5-year mortality in the highest LAS group (HR 1.13, p = 0.030, HR 1.17, p = 0.01, and HR 1.17, p = 0.02) comparing quartiles 2, 3, and 4, respectively, to quartile 1. Conclusion. Overall, outcomes in recipients with higher LAS are worse than those in patients with lower LAS. These data should inform more individualized evidence-based discussion during pretransplant counseling.","PeriodicalId":45795,"journal":{"name":"Journal of Transplantation","volume":"2015 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2015-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/836751","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65175937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
Risk Factors Associated with Increased Morbidity in Living Liver Donation 与活体肝脏捐献发病率增加相关的危险因素
IF 2.5 Q3 SURGERY Pub Date : 2015-12-15 DOI: 10.1155/2015/949674
H. Candido, E. A. da Fonseca, F. Feier, R. Pugliese, Marcel A. Benavides, E. Silva, Karina Gordon, M. G. de Abreu, J. Canet, P. Chapchap, J. S. Neto
Living donor liver donation (LDLD) is an alternative to cadaveric liver donation. We aimed at identifying risk factors and developing a score for prediction of postoperative complications (POCs) after LDLD in donors. This is a retrospective cohort study in 688 donors between June 1995 and February 2014 at Hospital Sírio-Libanês and A.C. Camargo Cancer Center, in São Paulo, Brazil. Primary outcome was POC graded ≥III according to the Clavien-Dindo classification. Left lateral segment (LLS), left lobe (LL), and right lobe resections (RL) were conducted in 492 (71.4%), 109 (15.8%), and 87 (12.6%) donors, respectively. In total, 43 (6.2%) developed POCs, which were more common after RL than LLS and LL (14/87 (16.1%) versus 23/492 (4.5%) and 6/109 (5.5%), resp., p < 0.001). Multivariate analysis showed that RL resection (OR: 2.81, 95% CI: 1.32 to 3.01; p = 0.008), smoking status (OR: 3.2, 95% CI: 1.35 to 7.56; p = 0.012), and blood transfusion (OR: 3.15, 95% CI: 1.45 to 6.84; p = 0.004) were independently associated with POCs. RL resection, intraoperative blood transfusion, and smoking were associated with increased risk for POCs in donors.
活体肝脏捐献(LDLD)是尸体肝脏捐献的另一种选择。我们的目的是确定供体LDLD后的危险因素并制定预测术后并发症(POCs)的评分。这是一项回顾性队列研究,在1995年6月至2014年2月期间,在巴西圣保罗的Sírio-Libanês医院和A.C. Camargo癌症中心对688名捐赠者进行了研究。根据Clavien-Dindo分级,主要终点为POC分级≥III。分别在492例(71.4%)、109例(15.8%)和87例(12.6%)供者中进行了左外侧段(LLS)、左肺叶(LL)和右肺叶切除(RL)。共有43例(6.2%)发生POCs, RL后比LLS和LL更常见(14/87(16.1%)比23/492(4.5%)和6/109(5.5%))。, p < 0.001)。多因素分析显示RL切除(OR: 2.81, 95% CI: 1.32 ~ 3.01;p = 0.008),吸烟状况(OR: 3.2, 95% CI: 1.35 ~ 7.56;p = 0.012),输血(OR: 3.15, 95% CI: 1.45 ~ 6.84;p = 0.004)与POCs独立相关。RL切除、术中输血和吸烟与供体POCs风险增加有关。
{"title":"Risk Factors Associated with Increased Morbidity in Living Liver Donation","authors":"H. Candido, E. A. da Fonseca, F. Feier, R. Pugliese, Marcel A. Benavides, E. Silva, Karina Gordon, M. G. de Abreu, J. Canet, P. Chapchap, J. S. Neto","doi":"10.1155/2015/949674","DOIUrl":"https://doi.org/10.1155/2015/949674","url":null,"abstract":"Living donor liver donation (LDLD) is an alternative to cadaveric liver donation. We aimed at identifying risk factors and developing a score for prediction of postoperative complications (POCs) after LDLD in donors. This is a retrospective cohort study in 688 donors between June 1995 and February 2014 at Hospital Sírio-Libanês and A.C. Camargo Cancer Center, in São Paulo, Brazil. Primary outcome was POC graded ≥III according to the Clavien-Dindo classification. Left lateral segment (LLS), left lobe (LL), and right lobe resections (RL) were conducted in 492 (71.4%), 109 (15.8%), and 87 (12.6%) donors, respectively. In total, 43 (6.2%) developed POCs, which were more common after RL than LLS and LL (14/87 (16.1%) versus 23/492 (4.5%) and 6/109 (5.5%), resp., p < 0.001). Multivariate analysis showed that RL resection (OR: 2.81, 95% CI: 1.32 to 3.01; p = 0.008), smoking status (OR: 3.2, 95% CI: 1.35 to 7.56; p = 0.012), and blood transfusion (OR: 3.15, 95% CI: 1.45 to 6.84; p = 0.004) were independently associated with POCs. RL resection, intraoperative blood transfusion, and smoking were associated with increased risk for POCs in donors.","PeriodicalId":45795,"journal":{"name":"Journal of Transplantation","volume":"2015 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2015-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/949674","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64177889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Plasma Exchange for the Recurrence of Primary Focal Segmental Glomerulosclerosis in Adult Renal Transplant Recipients: A Meta-Analysis 血浆置换治疗成人肾移植受者原发性局灶节段性肾小球硬化复发:荟萃分析
IF 2.5 Q3 SURGERY Pub Date : 2015-11-30 DOI: 10.1155/2015/639628
G. Vlachopanos, A. Georgalis, H. Gakiopoulou
Background. Posttransplant recurrence of primary focal segmental glomerulosclerosis (rFSGS) in the form of massive proteinuria is not uncommon and has detrimental consequences on renal allograft survival. A putative circulating permeability factor has been implicated in the pathogenesis leading to widespread use of plasma exchange (PLEX). We reviewed published studies to assess the role of PLEX on treatment of rFSGS in adults. Methods. Eligible manuscripts compared PLEX or variants with conventional care for inducing proteinuria remission (PR) in rFSGS and were identified through MEDLINE and reference lists. Data were abstracted in parallel by two reviewers. Results. We detected 6 nonrandomized studies with 117 cases enrolled. In a random effects model, the pooled risk ratio for the composite endpoint of partial or complete PR was 0,38 in favour of PLEX (95% CI: 0,23–0,61). No statistical heterogeneity was observed among included studies (I 2 = 0%, p = 0,42). On average, 9–26 PLEX sessions were performed to achieve PR. Renal allograft loss due to recurrence was lower (range: 0%–67%) in patients treated with PLEX. Conclusion. Notwithstanding the inherent limitations of small, observational trials, PLEX appears to be effective for PR in rFSGS. Additional research is needed to further elucidate its optimal use and impact on long-term allograft survival.
背景。原发性局灶节段性肾小球硬化(rFSGS)在移植后以大量蛋白尿的形式复发并不罕见,并且对同种异体移植肾的存活具有不利影响。一种假定的循环渗透性因子与导致血浆置换(PLEX)广泛应用的发病机制有关。我们回顾了已发表的研究,以评估PLEX在成人rFSGS治疗中的作用。方法。符合条件的文献通过MEDLINE和参考文献列表将PLEX或变体与常规治疗在诱导rFSGS患者蛋白尿缓解(PR)方面进行了比较。数据由两位审稿人并行抽取。结果。我们发现了6项非随机研究,纳入了117例病例。在随机效应模型中,部分或完全PR的综合终点的合并风险比为0.38,有利于PLEX (95% CI: 0.23 - 0.61)。纳入研究间无统计学异质性(i2 = 0%, p = 0,42)。平均进行9-26次PLEX治疗以达到PR。在接受PLEX治疗的患者中,由于复发而导致的同种异体肾移植损失较低(范围:0%-67%)。结论。尽管小型观察性试验存在固有局限性,但PLEX似乎对rFSGS患者的PR有效。进一步的研究需要进一步阐明其最佳使用和对长期同种异体移植存活的影响。
{"title":"Plasma Exchange for the Recurrence of Primary Focal Segmental Glomerulosclerosis in Adult Renal Transplant Recipients: A Meta-Analysis","authors":"G. Vlachopanos, A. Georgalis, H. Gakiopoulou","doi":"10.1155/2015/639628","DOIUrl":"https://doi.org/10.1155/2015/639628","url":null,"abstract":"Background. Posttransplant recurrence of primary focal segmental glomerulosclerosis (rFSGS) in the form of massive proteinuria is not uncommon and has detrimental consequences on renal allograft survival. A putative circulating permeability factor has been implicated in the pathogenesis leading to widespread use of plasma exchange (PLEX). We reviewed published studies to assess the role of PLEX on treatment of rFSGS in adults. Methods. Eligible manuscripts compared PLEX or variants with conventional care for inducing proteinuria remission (PR) in rFSGS and were identified through MEDLINE and reference lists. Data were abstracted in parallel by two reviewers. Results. We detected 6 nonrandomized studies with 117 cases enrolled. In a random effects model, the pooled risk ratio for the composite endpoint of partial or complete PR was 0,38 in favour of PLEX (95% CI: 0,23–0,61). No statistical heterogeneity was observed among included studies (I 2 = 0%, p = 0,42). On average, 9–26 PLEX sessions were performed to achieve PR. Renal allograft loss due to recurrence was lower (range: 0%–67%) in patients treated with PLEX. Conclusion. Notwithstanding the inherent limitations of small, observational trials, PLEX appears to be effective for PR in rFSGS. Additional research is needed to further elucidate its optimal use and impact on long-term allograft survival.","PeriodicalId":45795,"journal":{"name":"Journal of Transplantation","volume":"2015 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2015-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/639628","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65074119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
期刊
Journal of Transplantation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1